New Treatment of Knee Osteoarthritis

NCT06611098 | Recruiting DMC

• 1 other identifier: CLIN2403
• Study Type: interventional
• Target: 134
• Locations: 2 countries
• Sites: 2

Brief Summary

Osteoarthritis (OA) is a chronic degenerative joint disease characterized macroscopically by progressive damage of articular cartilage, joint space narrowing, subchondral bone remodelling, joint marginal osteophyte formation and synovitis. It is also characterized by a decrease of the concentration and molecular weight of the hyaluronic acid in the synovial fluid which ultimately leads to poor viscoelastic properties of synovial fluid and induction of proinflammatory pathways. The intra-articular injection of viscosupplementation gel (mainly exogenous hyaluronic acid) represents one of the most used therapeutic strategies to treat osteoarthritis symptoms. Several studies on knee Osteoarthritis, have shown that one or more weekly injection of viscosupplementation gel significantly relieves articular pain and ameliorates mobility and joint function for at least 6 months and more. Repeated courses of intra-articular injections are an effective and safe treatment for knee osteoarthritis symptoms. Based on studies conducted on intra-articular viscosupplementation gels, the most common side effects expected are local transient and short-lived adverse events such as pain, swelling and arthralgia in the site of administration, which are fully reversible in the days following the injection. Furthermore, such local effects may occur in a minority of cases and are usually treated conservatively with ice, non-steroidal anti-inflammatory drugs, and relative rest.

Conditions

Knee Osteoarthristis

Outcome Measures

Primary Outcomes (1)

• Evaluate the performance of ABIO3419 treatment versus the comparator in subjects at 3 months (V7) by assessing knee pain while walking on flat ground.

  Assessment by the subjects itself of the pain at 3-months (V7) compared to the baseline (V2 before initial injection) using a Visual Analogue Scale (VAS\_0-100mm). The statistical objective is to demonstrate the non-inferiority of ABIO3419 compared to the comparator.

  Month 3 after the last injection

Secondary Outcomes (8)

• Evaluate the pain of the treated knee when walking on a flat ground throughout the study.

  Before intra-articular injections at 1 week, 2 week and then at 2 week, 1 month and 6 month after the last injection

• Evaluate the overall safety throughout the study.

  immediately after first injection, before and immediately after the injections at 1 week and 2 weeks, and then at 2 weeks, 1 month, 3 months and 6 months.

• Evaluate the device related complications rates throughout the study

  Immediately after first injection, before and immediately after the injections at 1 week and 2 weeks, then at 2 weeks, 1 month, 3 months and 6 months after the last injection

• Evaluate the general health status of the treated knee

  Baseline (before initial injection), 1 week and 2 weeks after the first injection (before 2nd and 3rd injections) then 2 weeks, 1 month, 3 months and 6 months after the last injection.

• Evaluate concomitant analgesic consumption of subjects

  1 week before the first injection, 1 week and 2 weeks after the first injection then 2 weeks, 1 month, 3 months and 6 months after the last injection

Study Arms (2)

ABIO3419

EXPERIMENTAL

Patients will be enrolled and randomised to receive ABIO3419 by intra-articular injection.

Device: Viscosupplements

Synvisc

ACTIVE COMPARATOR

Patients will be enrolled and randomised to receive Synvisc(r) by intra-articular injection.

Device: Viscosupplements

Interventions

Viscosupplements DEVICE

intra-articular injection

ABIO3419; Synvisc

Eligibility Criteria

• Age: 35 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \. Voluntarily given informed consent to investigation participation in writing encompassing consent to data recording and verification procedures.
• \. Male and female subjects, aged 35 to 85 years (inclusive).
• \. Subjects affected by knee osteoarthritis, as defined by American College of Rheumatology (ACR) clinical and radiographic criteria for OA of the knee, and meeting the following conditions:
• Non-severe Grade 2 to 3 osteoarthritis of the knee according to the Kellgren-Lawrence (KL) classification, confirmed by an extension face X-rays shot, supported by flexion face X-rays shot (optional) obtained within 6 months from the screening visit.
• Subjects suffering from OA symptoms of the target knee for at least 6 months prior to the screening visit.
• \. Pain during walking on flat ground in the target knee of at least 40 mm and maximum 80 mm on a 0-100 mm VAS at the baseline visit (Visit 2).
• \. Subjects in treatment failure of first line treatment with oral NSAIDS
• \. Women of childbearing potential must have a negative urine pregnancy test prior to each injection.
• \. Subject who is able to comply with the study requirements, at the Investigator\'s appreciation.

You may not qualify if:

• \- 1. Pregnant and breastfeeding women
• \. Subject with bilateral OA of the knees is excluded if one of the following points is present on the non-targeted knee has:
• a visual analog scale (VAS) score greater than 30mm (\> 30mm),
• a KL score is greater than 2 (\>2)
• a dedicated pain relief medicine consumption.
• \. Subject suffering from a severe or progressive disease or any other pathology which, according to the investigator, may interfere with evaluation of the results of the study: diabetes, autoimmune pathology, cardiac pathologies, hepatic deficiency, epilepsy, porphyria, rheumatoid arthritis or other systemic inflammatory process.
• \. Subject who has a known history of severe multiple allergies, angioedema or anaphylactic shock according to the investigator opinion.
• \. Subject with a known allergy or hypersensitivity to Hyaluronic Acid or bovine collagen.
• \. Subject with a past history of severe streptococcal disease or an active streptococcus infection according to the investigator opinion.
• \. Subject with an infections, inflammation or skin diseases in the area of the injection site.
• \. Subject with a disorder that may impact wound healing such as connective tissue or immunosuppressive disorder.
• \. Subject having received chemotherapy agents, immunosuppressive medications within the past 3 months.
• \. Subject with bleeding disorders or subject having received medication (anti-platelet agents and anticoagulant) that will likely increase the risk of bleeding within the past 24 hours before injections.
• \. Subjects having received:
• Intra-articular steroid injections within 60 days of the baseline visit or during study participation. Oral corticosteroids within four weeks of the screening visit or during study participation.

Sponsors & Collaborators

• Symatese: lead

Study Sites (2)

IRIS CRO

Mtskheta, Georgia, 3300, Georgia

NOT YET RECRUITING

IRIS CRO

Riga, Latvia, 1002, Latvia

RECRUITING

Study Officials

• Kristaps KNOHENFELDS

  Veselibas Centrs ZIN

  PRINCIPAL INVESTIGATOR

• Kalvis KRASTINS

  Kalvja Krastina private practice

  PRINCIPAL INVESTIGATOR

• Manaa Zodelava

  JSC "Evex Hospitals" Caraps Medline

  PRINCIPAL INVESTIGATOR

• Nano Emukhvari

  LLC Israel-Georgian Medical Research Clinic Healthycore

  PRINCIPAL INVESTIGATOR

• Luba Lagvilava

  Consilium Medulla Multiprofile Clinic

  PRINCIPAL INVESTIGATOR

• Ketevan Tsintsadze

  LTD HEALTH

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Carla LIPPENS

CONTACT

+33 04 28 38 38 10; carla.lippens@complifegoup.com

Sébastien GUYON

CONTACT

+33 04 78 56 72 80; s.guyon@symatese.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 23, 2024
• First Posted: September 24, 2024
• Study Start: February 21, 2025
• Primary Completion: September 1, 2025
• Study Completion: March 1, 2026
• Last Updated: February 26, 2025

Record last verified: 2025-02

Data Sharing

• IPD Sharing: Will not share

Locations

LA (1); GE (1)